IN8bio, Inc. (INAB)

NASDAQ: INAB · IEX Real-Time Price · USD
1.000
-0.030 (-2.92%)
At close: Apr 22, 2024, 4:00 PM
0.950
-0.050 (-4.99%)
After-hours: Apr 22, 2024, 7:58 PM EDT
-2.92%
Market Cap 43.28M
Revenue (ttm) n/a
Net Income (ttm) -30.01M
Shares Out 43.29M
EPS (ttm) -1.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 214,428
Open 1.040
Previous Close 1.030
Day's Range 0.995 - 1.040
52-Week Range 0.650 - 3.950
Beta -0.01
Analysts Strong Buy
Price Target 9.30 (+830.09%)
Earnings Date May 10, 2024

About INAB

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 31
Stock Exchange NASDAQ
Ticker Symbol INAB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for INAB stock is "Strong Buy." The 12-month stock price forecast is $9.3, which is an increase of 830.09% from the latest price.

Price Target
$9.3
(830.09% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc.  (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho...

6 days ago - GlobeNewsWire

IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024

- Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue - Gamma-delta nsCAR platform emerging as an advanced technolo...

13 days ago - GlobeNewsWire

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Reported the First-Ever Durable Persistence of an Allogeneic Cellular Therapy from a Phase 1 Study of INB-100 in Leukemia where 100% of Evaluable Patients (n=10) Treated Remained in Remission, includi...

5 weeks ago - GlobeNewsWire

IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024

New preclinical data demonstrating proof-of-concept for the non-signaling gamma-delta T cell CAR (nsCAR) platform candidate targeting CD-33 and CD-123 will be presented. The platform has demonstrated ...

6 weeks ago - GlobeNewsWire

IN8bio to Present at Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)---- $INAB #biotech--IN8bio to Present at Upcoming Investor Conferences.

2 months ago - Business Wire

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Peer-reviewed publication discusses current strategy and future direction of new treatment for glioblastoma using novel gamma-delta T cell based adoptive cellular therapy Peer-reviewed publication dis...

2 months ago - GlobeNewsWire

IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today highlighted recent...

3 months ago - GlobeNewsWire

IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced positive...

4 months ago - GlobeNewsWire

IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement

Initial closing of $14.4 million to support operational execution and extend cash runway into 2025 with potential for up to $32.5 million in additional capital at increasing valuations

4 months ago - GlobeNewsWire

IN8bio Appoints Dr. Corinne Epperly to Board of Directors

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the appo...

4 months ago - GlobeNewsWire

IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia

NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the Comp...

4 months ago - GlobeNewsWire

IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

All patients treated with INB-200 who completed mandated doses to date have exceeded a progression-free survival (PFS) of seven months

5 months ago - GlobeNewsWire

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

Company will present “late-breaker” poster detailing updated clinical data from Phase 1 trial of INB-200 Company-sponsored Phase 2 trial of INB-400 to be showcased in Trials-in-Progress (TIPs) poster ...

5 months ago - GlobeNewsWire

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financia...

5 months ago - GlobeNewsWire

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new biol...

6 months ago - GlobeNewsWire

IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today presented new posi...

6 months ago - GlobeNewsWire

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an abstract deta...

6 months ago - GlobeNewsWire

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William ...

6 months ago - GlobeNewsWire

IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma

NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the comp...

6 months ago - GlobeNewsWire

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting

NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced two pos...

7 months ago - GlobeNewsWire

IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, is proud to announce it...

7 months ago - GlobeNewsWire

IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William...

7 months ago - GlobeNewsWire

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced signifi...

7 months ago - GlobeNewsWire

IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William...

8 months ago - GlobeNewsWire

IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced William ...

8 months ago - GlobeNewsWire